BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

about

TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells.Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs

P2860

Q38656329-FC0BFF2A-1DD2-41EF-BECC-B5A549DCED93 Q58733026-2355BB92-02B7-455B-8767-A07250C5B31F

P2860

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

Item

http://www.wikidata.org/entity/Q47095865

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

@en

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

@nl

type

Item

label

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

@en

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

@nl

prefLabel

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

@en

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

@nl

P1476

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

@en

P2093

Shingo Nakayamada

http://www.w3.org/2001/XMLSchema#string

Yoshiya Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

BAFF, APRIL and their receptors: structure, function and signaling

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity

Follicular helper CD4 T cells (TFH)

BAFF regulates follicular helper t cells and affects their accumulation and interferon-γ production in autoimmunity.

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

The TNF family members BAFF and APRIL: the growing complexity.

The function of BAFF on T helper cells in autoimmunity

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF

P2888

s41232-016-0015-4

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S41232-016-0015-4

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013398997

http://www.w3.org/2001/XMLSchema#string

P698

29259679

http://www.w3.org/2001/XMLSchema#string

P932

5725651

http://www.w3.org/2001/XMLSchema#string

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

about

P2860

P2860

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P6179

P698

P932